Our 505(b)(2) Expertise
At present, LGM Pharma supports 120+ drug development programs pursuing the 505(b)(2) pathway, in just about every therapeutic category and at every stage (pre-clinical to commercial).
Programs by stage of development:
Programs by stage of dosage form:

LGM can help ensure your project is successful by providing:

  • Access to a portfolio of over 2,000 APIs from every therapeutic category to support any stage of development, from early feasibility to commercial production.
  • A consultative approach to understand your unique needs.
  • Market insight and industry knowledge to ensure the API for your project meets the required specifications for your unique delivery system.
  • Custom synthesis / API modifications via LGM’s 150+ qualified API manufacturers globally that comply with CGMP guidelines and are FDA inspected.
  • Support programs as a primary source, from R&D through commercialization.
  • Risk mitigation strategies for your supply chain by providing secondary or tertiary sources from different geographical regions.
  • Quality & regulatory documentation / support required for regulatory submissions in the USA, EU and other highly regulated markets.
  • Sourcing and supply chain expertise, handling all aspects of global logistics, customs / FDA clearance, in order to deliver the API to your door.
  • Introductions to CDMO’s specializing in formulation development and commercial manufacturing of Finished Dosage Form products.

Working on a project using the 505(b)(2) pathway?

We’ve been working with clients for years on 505(b)(2) programs. At present, we are supporting over 120 API programs utilizing the 505(b)(2) pathway.

CONTACT US

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

Click here to read our press release
This website uses cookies. By using our site, you agree to our terms of service